Sangart Adds $50M to Their Total Equity Funding

Sangart Inc. will be looking at further clinical development as they receive their Series G equity funding worth $50 million from Leucadia National Corporation. The latter is already an existing investor.

Sangart Inc. has now raised over $280 millionĀ in financing.

The company’s CEO Brian O’Callaghan happily shares more information about this recent funding in this e-interview with Lead411:

Read More